title: Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.
abstract: To estimate the risk of secondary leukemias after treatment with etoposide (VP-16), we evaluated subjects treated for Langerhans' cell histiocytosis (LCH) according to cooperative protocols in Italy or in Austria, Germany, Holland and Switzerland (AGDS). For each subject, information was collected on the cumulative dosages of chemotherapy and radiotherapy received, vital status and occurrence of secondary leukemia. The expected number of leukemias was estimated using age-specific incidence rates from the cancer registries in Italy and Germany. Standardized incidence ratios (SIR) were used to measure the risk of secondary leukemia among LCH patients. Five leukemias occurred among the 241 Italian study patients (SIR 520), whereas no cases were reported among the 363 AGDS patients. Interestingly, and in contrast to previous descriptions of epipodophyllotoxin-related leukemias which are mostly FAB M4 or M5, these leukemias showed typical FAB M3 features, and received a dose of VP-16 > 4,000 mg/m2. Among the AGDS cohort, very few subjects were exposed to high doses of VP-16. The risk of secondary acute non-lymphoblastic leukemia (s-ANLL) among the Italian subjects exposed to VP-16 was more than 1,000 times greater than expected. The study suggests that high doses of VP-16 appear to increase the risk of s-ANLL in LCH patients. The fact that all the leukemias described in the Italian LCH cohort were promyelocytic, and evidence of a higher incidence of promyelocytic leukemias among Italians and Latinos, suggest that high doses of etoposide in subjects of Latino origin may lead to aberrations on chromosomes 15 and 17.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: R
authors.initials: R
authors.lastname: Haupt
authors.forename: T R
authors.initials: TR
authors.lastname: Fears
authors.forename: A
authors.initials: A
authors.lastname: Heise
authors.forename: H
authors.initials: H
authors.lastname: Gadner
authors.forename: G
authors.initials: G
authors.lastname: Loiacono
authors.forename: M
authors.initials: M
authors.lastname: De Terlizzi
authors.forename: M A
authors.initials: MA
authors.lastname: Tucker
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001317:Austria / Q000208:ethnology; D002648:Child; D002675:Child, Preschool; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D015331:Cohort Studies; D005047:Etoposide / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007558:Italy / Q000453:epidemiology; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D018570:Risk Assessment; D012737:Sex Factors; D013557:Switzerland / Q000453:epidemiology; D014178:Translocation, Genetic
chemical_list: D005047:Etoposide